AIPL1

Across TCGA pan-cancer cohorts, AIPL1 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of AIPL1’s most consistent transcriptional readouts.

The strongest signal is observed in lung adenocarcinoma (LUAD), where AIPL1 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types AIPL1 is over-expressed in tumor, although a few such as LUAD and LSCC show the opposite, repressed pattern.

LUAD, LSCC, and PDAC are the cancer types where AIPL1 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in AIPL1 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LUAD	Female	III,IV	−0.665	<.001	9	view →
LSCC	Female	All	−0.544	<.001	9	view →
PDAC	All	All	−0.259	<.001	6	view →
HNSC	Male	II,III,IV	−0.209	<.001	6	view →
CCRCC	All	II,III,IV	−0.084	.021	6	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

AIPL1–LUAD

Open the LUAD breakdown →